Amycretin is one of the most talked-about names in the next wave of obesity drugs, for two reasons: it hits two appetite systems with a single molecule, and it comes as both a pill and an injection. It is still investigational, but its early human numbers are large enough to have made it a headline.
In plain terms: it combines the GLP-1 effect you know from semaglutide with a second satiety hormone — amylin — all in one drug, and one version is a tablet.
What it is
Amycretin is a unimolecular (single-molecule) co-agonist of the GLP-1 receptor and the amylin receptor1. "Co-agonist" means one molecule switches on two targets; "unimolecular" means it's genuinely one compound doing both jobs, not two drugs mixed together. It's a Novo Nordisk candidate, developed in oral and subcutaneous forms.
The two targets are complementary appetite systems:
- GLP-1 receptor — the incretin target that semaglutide uses to curb appetite.
- Amylin receptor — amylin is a pancreatic satiety hormone that regulates appetite and blood glucose; it's the system the amylin analog cagrilintide targets4.
The mechanism: two appetite systems, one molecule
Why bother combining them? Because single-target drugs eventually hit an efficacy ceiling — there's only so much appetite suppression one pathway delivers. Amycretin's dual-agonist design is built to push past that plateau by engaging hindbrain satiety pathways through both receptors at once, while also slowing gastric emptying so meals feel filling for longer3.
GLP-1 and amylin are a natural pairing: they act on overlapping but distinct satiety circuits, so hitting both can be synergistic rather than simply additive3. That's the same logic behind pairing cagrilintide with semaglutide — except amycretin does it inside one molecule.
What the trials actually found
Amycretin's early clinical data is what drove the excitement — and it exists for both formulations:
| Study | Design | Key result | Year |
|---|---|---|---|
| Gasiorek et al. — first-in-human1 | Phase 1, double-blind, placebo-controlled, single + multiple ascending doses | Established safety, tolerability, and pharmacology in overweight/obese adults | 2025 |
| Dahl et al. — subcutaneous2 | Phase 1b/2a, once-weekly, up to 36 weeks | Assessed safety and bodyweight effects of the injectable form | 2025 |
On the numbers, a 2026 review summarizing these trials reports up to ~13.1% weight loss with oral amycretin at 12 weeks and up to ~24.3% with the subcutaneous form at 36 weeks3. For context, ~24% at 36 weeks is in the territory of the strongest injectables in development — from a drug that also has an oral version.
In plain terms: in early trials both the pill and the shot produced large weight loss, with the injection (given longer) reaching the higher figure.
A pill *and* an injection
One detail sets amycretin apart: it's being developed as an oral tablet as well as a subcutaneous injection1. Peptide-style drugs are notoriously hard to deliver by mouth — the gut tends to destroy them — so an oral form that still produces double-digit weight loss is a genuine engineering result, and potentially a big deal for people who would rather not inject.
Side effects and safety
The safety picture is early but familiar. Because both of amycretin's targets are appetite-gut hormones, its side-effect profile in trials has been consistent with the incretin-based class3 — meaning the dominant effects are gastrointestinal (nausea, vomiting, diarrhea), typically dose-dependent and worst during dose escalation, which is why the trials escalated the dose gradually2.
The honest caveats:
- It's early-stage evidence. These are phase-1 and early phase-2 trials — short, and smaller than the large trials that establish long-term safety. Rare and long-term risks aren't characterized yet.
- The big numbers are preliminary. The ~13% and ~24% figures come from early studies3; larger, longer trials are needed to confirm they hold.
Investigational status
To be plain: amycretin is not an approved medicine. As of 2026 it is in clinical development (a Novo Nordisk candidate) with phase-1 and early phase-2 data published and larger trials expected. Everything solid known about it comes from those studies. This page explains what it is and what the trials showed — not how to use it — and it takes no position on sourcing.
The short version
Amycretin is a single-molecule co-agonist that switches on both the GLP-1 and amylin receptors, pairing the incretin effect of semaglutide with a second satiety hormone to push weight loss past single-target ceilings3. Early trials of both its oral and injectable forms produced large weight loss (roughly 13% oral at 12 weeks, 24% injected at 36 weeks)3, but it is investigational, phase-1/2-stage, and unapproved — an educational overview only, not medical advice.